Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016

Introduction. There is no treatment for recurrence of head and neck squamous cell carcinoma, which significantly increases the overall survival (OS) of patients.The study objective is to analyze the results of treatment of patients with recurrences of squamous cell carcinoma of the head and neck and...

Full description

Bibliographic Details
Main Authors: R. Yu. Karabut, A. V. Vazhenin, E. Y. Mozerova, T. M. Sharabura, M. M. Sarycheva, A. O. Guz, A. S. Zakharov
Format: Article
Language:Russian
Published: ABV-press 2020-04-01
Series:Опухоли головы и шеи
Subjects:
Online Access:https://ogsh.abvpress.ru/jour/article/view/472
_version_ 1797876161894678528
author R. Yu. Karabut
A. V. Vazhenin
E. Y. Mozerova
T. M. Sharabura
M. M. Sarycheva
A. O. Guz
A. S. Zakharov
author_facet R. Yu. Karabut
A. V. Vazhenin
E. Y. Mozerova
T. M. Sharabura
M. M. Sarycheva
A. O. Guz
A. S. Zakharov
author_sort R. Yu. Karabut
collection DOAJ
description Introduction. There is no treatment for recurrence of head and neck squamous cell carcinoma, which significantly increases the overall survival (OS) of patients.The study objective is to analyze the results of treatment of patients with recurrences of squamous cell carcinoma of the head and neck and to assess the impact of risk factors for relapse, as well as different treatment options for relapse on OS. Materials and methods. In the period from 2012 to 2016, 182 patients with relapses of squamous cell carcinoma of the larynx, oral cavity and tongue received treatment in the Chelyabinsk regional clinical center of Oncology and nuclear medicine. The group 1 included 66 patients with resectable relapse who were operated. The group 2 consisted of 25 patients who received a course of radiation therapy. The group 3 consisted of 46 patients who underwent chemotherapeutic treatment of relapse. The group 4 was represented by combined treatment (surgery + radiation therapy), this group included 9 people. The group 5 consisted of those of patients who were not specifically treated for relapse because of the low Karnofsky index in patients (<70 %). Results. OS among patients who received special treatment was significantly higher compared with the group of symptomatic therapy. The median OS in the special treatment group was 40 months, and without it – 18 months. Comparing all types for treating relapse, the highest rates of OS were in the surgical treatment group. OS rates in combined therapy group and radiotherapy group were comparable rate in the radiotherapy. The lowest OS rate was after chemotherapy (only 21 months).Conclusion. Surgery is the optimal method for treating recurrent squamous cell carcinoma of head and neck, if it is resectable. If surgical treatment is not possible, no other method significantly increases the OS. If the overall status of the patient is normal, re-radiation or polychemotherapy may be performed. A limited category of patients can be subjected to combined treatment for relapse.
first_indexed 2024-04-10T01:58:47Z
format Article
id doaj.art-8d078d97b1da41c08decc52b1787f4c8
institution Directory Open Access Journal
issn 2222-1468
2411-4634
language Russian
last_indexed 2024-04-10T01:58:47Z
publishDate 2020-04-01
publisher ABV-press
record_format Article
series Опухоли головы и шеи
spelling doaj.art-8d078d97b1da41c08decc52b1787f4c82023-03-13T08:43:21ZrusABV-pressОпухоли головы и шеи2222-14682411-46342020-04-01101202810.17650/2222-1468-2020-10-1-20-28378Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016R. Yu. Karabut0A. V. Vazhenin1E. Y. Mozerova2T. M. Sharabura3M. M. Sarycheva4A. O. Guz5A. S. Zakharov6ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»; ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава РоссииГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»; ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава РоссииГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»; ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава РоссииГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»Introduction. There is no treatment for recurrence of head and neck squamous cell carcinoma, which significantly increases the overall survival (OS) of patients.The study objective is to analyze the results of treatment of patients with recurrences of squamous cell carcinoma of the head and neck and to assess the impact of risk factors for relapse, as well as different treatment options for relapse on OS. Materials and methods. In the period from 2012 to 2016, 182 patients with relapses of squamous cell carcinoma of the larynx, oral cavity and tongue received treatment in the Chelyabinsk regional clinical center of Oncology and nuclear medicine. The group 1 included 66 patients with resectable relapse who were operated. The group 2 consisted of 25 patients who received a course of radiation therapy. The group 3 consisted of 46 patients who underwent chemotherapeutic treatment of relapse. The group 4 was represented by combined treatment (surgery + radiation therapy), this group included 9 people. The group 5 consisted of those of patients who were not specifically treated for relapse because of the low Karnofsky index in patients (<70 %). Results. OS among patients who received special treatment was significantly higher compared with the group of symptomatic therapy. The median OS in the special treatment group was 40 months, and without it – 18 months. Comparing all types for treating relapse, the highest rates of OS were in the surgical treatment group. OS rates in combined therapy group and radiotherapy group were comparable rate in the radiotherapy. The lowest OS rate was after chemotherapy (only 21 months).Conclusion. Surgery is the optimal method for treating recurrent squamous cell carcinoma of head and neck, if it is resectable. If surgical treatment is not possible, no other method significantly increases the OS. If the overall status of the patient is normal, re-radiation or polychemotherapy may be performed. A limited category of patients can be subjected to combined treatment for relapse.https://ogsh.abvpress.ru/jour/article/view/472рецидив плоскоклеточного рака головы и шеи, повторное облучение, химиотерапия, хирургическое лечение, выживаемость
spellingShingle R. Yu. Karabut
A. V. Vazhenin
E. Y. Mozerova
T. M. Sharabura
M. M. Sarycheva
A. O. Guz
A. S. Zakharov
Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016
Опухоли головы и шеи
рецидив плоскоклеточного рака головы и шеи, повторное облучение, химиотерапия, хирургическое лечение, выживаемость
title Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016
title_full Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016
title_fullStr Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016
title_full_unstemmed Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016
title_short Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016
title_sort recurrent squamous cell carcinoma of head and neck results of treatment in the chelyabinsk regional clinical center of oncology and nuclear medicine in 2012 2016
topic рецидив плоскоклеточного рака головы и шеи, повторное облучение, химиотерапия, хирургическое лечение, выживаемость
url https://ogsh.abvpress.ru/jour/article/view/472
work_keys_str_mv AT ryukarabut recurrentsquamouscellcarcinomaofheadandneckresultsoftreatmentinthechelyabinskregionalclinicalcenterofoncologyandnuclearmedicinein20122016
AT avvazhenin recurrentsquamouscellcarcinomaofheadandneckresultsoftreatmentinthechelyabinskregionalclinicalcenterofoncologyandnuclearmedicinein20122016
AT eymozerova recurrentsquamouscellcarcinomaofheadandneckresultsoftreatmentinthechelyabinskregionalclinicalcenterofoncologyandnuclearmedicinein20122016
AT tmsharabura recurrentsquamouscellcarcinomaofheadandneckresultsoftreatmentinthechelyabinskregionalclinicalcenterofoncologyandnuclearmedicinein20122016
AT mmsarycheva recurrentsquamouscellcarcinomaofheadandneckresultsoftreatmentinthechelyabinskregionalclinicalcenterofoncologyandnuclearmedicinein20122016
AT aoguz recurrentsquamouscellcarcinomaofheadandneckresultsoftreatmentinthechelyabinskregionalclinicalcenterofoncologyandnuclearmedicinein20122016
AT aszakharov recurrentsquamouscellcarcinomaofheadandneckresultsoftreatmentinthechelyabinskregionalclinicalcenterofoncologyandnuclearmedicinein20122016